Drugs / anti-human T lymphocyte porcine immunoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06613880 Background | Oct 2024 → Jan 2026 overdue | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 3 | NCT07345000 Comparator | Jan 2026 → Oct 2029 expected | idiopathic aplastic anemia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-human T lymphocyte porcine immunoglobulin | “anti-human T lymphocyte porcine immunoglobulin (p-ALG)” NCT06613880 ↗ |
| Known as | pALG | “anti-human T lymphocyte porcine immunoglobulin (p-ALG)” NCT06613880 ↗ |
| Modality | Protein / enzyme biologic | “anti-human T lymphocyte porcine immunoglobulin (p-ALG)” NCT06613880 ↗ |